Brendan Horton

Expansion of tumor-reactive CD8 ⁺ T cell clonotypes occurs in the spleen in response to immune checkpoint blockade

Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy

Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer

A prime editor mouse to model a broad spectrum of somatic mutations in vivo

Overcoming lung cancer immunotherapy resistance by combining nontoxic variants of IL-12 and IL-2

Lack of CD8 ⁺ T cell effector differentiation during priming mediates checkpoint blockade resistance in non–small cell lung cancer

328 Batf3 dendritic cells and 4–1BB/4–1BB ligand axis are required at the effector phase within the tumor microenvironment for anti-PD-L1 efficacy

664 Pulmonary priming of tumor-reactive CD8⁺ T cells by DC1 is impaired by regulatory T cells

A Tumor Cell-Intrinsic Yin-Yang Determining Immune Evasion

Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy

Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment

The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment

Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment